Characterization of drug-resistance mutations in HIV-1 isolates from non-HAART and HAART treated patients in Burkina Faso

W. M. Nadembega, S. Giannella, J. Simpore, F. Ceccherini-Silberstein, V. Pietra, A. Bertoli, S. Pignatelli, M. C. Bellocchi, J. B. Nikiema, G. Cappelli, A. Bere, V. Colizzi, C. P. Perno, S. Musumeci

Research output: Contribution to journalArticle

Abstract

Non-B HIV subtypes have been estimated to account for 88% of HIV infections in the world. These subtypes are particularly relevant in view of the availability of antiretroviral (ARV) drugs, since subtype-specific mutations are associated with drug-resistance in developing countries. Therefore, the pol gene sequences in HIV-1 isolates were examined from the three distinct groups of 39 infected patients from Ouagadougou in Burkina Faso: 17 patients who had not received any antiretroviral therapy (ART); 16 patients received ART, and 6 HIV-infected children, from infected mothers, received a single Nevirapine dose prophylaxis during birth. HIV-1 pol sequencing was successful for 29 samples. As expected, all patients presented the common (non-B subtype) M36I polymorphism and 26/29 (90%) the K20I mutation. Phylogenetic studies showed high predominance of recombinant HIV-1 strains: CRF06_cpx 16/29 (55.17%), CRF02_AG 9/29 (31.03%), A1 2/29 (6.89%), G 1/29 (3.44%), and CRF09_cpx 1/29 (3.44%). Two twins showed, 6 months after birth, a NNRTI-mutation (Y181C/Y). During the same period, the twin mother presented a different NNRTI-mutation (V106I), thus suggesting that the different blood drug concentration may determine a different drug-resistance pathway. Among 17 non-highly active antiretroviral therapy (HAART) patients, 3/17 (17.64%) presented virus with reverse transcriptase (RT) mutations [V118I:1/17 patients (5.88%), V179E: 2/17 patients (11.76%)]. 10/17(58.82%) presented virus with minor protease (PR) mutations [L63P: 5/17 patients (29.41%), V77I: 3/17 patients (17.64%), L10I:2/17 patients (11.76%)]. 4/17 patients did not show any PR and RT mutations (23.52%). Among six HAART-treated patients, 6/6 and 3/6 had M36I and L63LP protease minor subtypes, respectively; and only two (33.33%) presented virus with K103N mutation. The low prevalence of drug-resistant associated mutations in Burkina Faso is encouraging. However, further studies with a larger cohort with a high non-B subtype prevalence are necessary to optimize ART in developing countries.

Original languageEnglish
Pages (from-to)1385-1391
Number of pages7
JournalJournal of Medical Virology
Volume78
Issue number11
DOIs
Publication statusPublished - Nov 2006

Keywords

  • ARV
  • Burkina Faso
  • Drug-resistance
  • Genotype
  • HIV-1
  • Vertical transmission

ASJC Scopus subject areas

  • Virology

Fingerprint Dive into the research topics of 'Characterization of drug-resistance mutations in HIV-1 isolates from non-HAART and HAART treated patients in Burkina Faso'. Together they form a unique fingerprint.

  • Cite this

    Nadembega, W. M., Giannella, S., Simpore, J., Ceccherini-Silberstein, F., Pietra, V., Bertoli, A., Pignatelli, S., Bellocchi, M. C., Nikiema, J. B., Cappelli, G., Bere, A., Colizzi, V., Perno, C. P., & Musumeci, S. (2006). Characterization of drug-resistance mutations in HIV-1 isolates from non-HAART and HAART treated patients in Burkina Faso. Journal of Medical Virology, 78(11), 1385-1391. https://doi.org/10.1002/jmv.20709